Navigation Links
Auxilium Pharmaceuticals to Present at the 2012 Barclays Capital Global Healthcare Conference
Date:3/8/2012

ctelion Pharmaceuticals Ltd. has development and commercial rights for XIAFLEX in Australia, Brazil, Canada and Mexico. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has three projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease, in phase IIa of development for the treatment of Frozen Shoulder syndrome (Adhesive Capsulitis) and in phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to present at the 2012 Barclays Capital Global Healthcare Conference; and products in development for Peyronie's disease, Frozen Shoulder syndrome and cellulite; and all other statements containing projections, statements of future performance or expectations, our beliefs or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Forward-looking statements can generally be identified by words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, beliefs, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... time online has the potential to ward off depression ... to research published online in The Journals ... . In the article " Internet Use and ... A Longitudinal Analysis ," the authors report that Internet ... 33 percent among their study sample. , Late-life ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... CHERRY HILL, N.J., Sept. 11 Nuvilex, Inc. (OTC ... its joint venture partner, has informed the company that ... its homeopathic remedy for helping to prevent and treat ... The Reme-Flu(TM) formula consists of a two-part protocol. ...
... Bupa,s Latin America and Caribbean,operation -- a division ... the launch of the international Ecuador Challenge, which will,take ... families survive on,average on just $4 a day. Some ... Ecuador until November 29 to build essential health and ...
... , MISSISSAUGA, Ontario, Sept. 11 JAG ... agreement with The Investor Relations Group, Inc. ("IRG"), pursuant to which ... the Company in accordance with the terms of the agreement. As ... to IRG. , , "We are very excited ...
... , , YARDLEY, Pa., Sept. 11 ... soft tissue and skeletal repair of the extremities, announced today that ... Chairman of the Board, effective immediately. , , ... as it moves from product development to commercialization," said Zev Scherl, ...
... , IRVING, Texas, Sept. 11 ... 643 on its third annual Inc. 5000, an exclusive ranking ... most comprehensive look at the most important segment of the ... rental car service Zipcar, and beverage maker Honest Tea are ...
... - HTDS www.htdsmedical.com The company is pleased ... Hope www.mellowhope.com has successfully completed and delivered ... Bangladesh. , In developing countries, over 11 million children ... nearly three quarters of these deaths result from infectious ...
Cached Medicine News:Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2Health News:John C. Moran Named CEO at Core Essence Orthopaedics 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 2Health News:Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh 3
... use in settings where a more secure band is ... but difficult to remove wristband is appropriate. The design ... time. One band to be placed on the wrist ... the first need to be replaced. This is particularly ...
IDENTI-MATCH II is a combination of the IDENTI-MATCH Blood Recipient Identification System and an admitting band. It has been designed for those facilities using label-based patient ID systems....
Zebras H 2824-Z Healthcare Starter Kit includes everything you need to start printing wristbands today: the H 2824-Z direct thermal printer, a pre-installed Media Adapter Guide, and a roll of adult-s...
... VerdaSees Navigaton™ software facilitates real time ... two modules: the first module is ... reader devices and the database where ... second module is the user interface, ...
Medicine Products: